FDA panel to consider KP.2 subvariant for updated vaccine
Summary: FDA staff recommends considering the KP.2 subvariant, now dominant in the U.S., for the next COVID vaccine. The advisory committee will vote on updating the vaccine formula for 2024-2025. Current vaccines show effectiveness against evolving strains, but waning over time. WHO advises a monovalent JN.1 lineage vaccine. FDA will consider recommendations for updated vaccines amid low uptake rates.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings